1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Recalls

Q1 Recalls Snapshot: Recalled Units Skyrocket 457%; Largest Quarterly Number In 13 Years

 
• By Shawn M. Schmitt

More medical devices were recalled by manufacturers in the first quarter of 2018 than in any quarter since at least 2005, with 343 initiated. Moreover, there were 208.4 million units recalled in Q1 '18 – more units than in all of 2017. Check out our Q1 recalls infographic.

Q1 written on a speechbubble

More medical devices were recalled by manufacturers in the first quarter of 2018 than in any quarter since at least 2005, consulting firm Stericycle said in its most recent recalls index. There were 343 recall events initiated in Q1, a 126% increase over Q4 2017, when there were 152. Q1 2018 had the largest number of recall events in a given quarter since Stericycle began tracking medical device recalls 13 years ago. Moreover, the number of recalled device units also skyrocketed, from 37.4 million in Q4 '17 to 208.4 million in Q1 '18 – an increase of 457%. Stericycle, which gathered its recalls data from FDA Enforcement Reports, noted that the number of Q1 recalled units was more than all of 2017's recalled units combined (182.2 million). Troubles with software, mislabeling and quality were the top 3 causes of recall events in Q1 2018 – the same as in Q4 2017.

From the editors of The Gray Sheet

More from Recalls

More from Policy & Regulation

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.